PatientsVille.com Logo

VISION BLURRED and Mirtazapine

PatientsVille

VISION BLURRED Symptoms and Causes

The cornea and lens of your eye helps you focus. Refractive errors are vision problems that happen when the shape of the eye keeps you from focusing well. The cause could be the length of the eyeball (longer or shorter), changes in the shape of the cornea, or aging of the lens.

Four common refractive errors are

  • Myopia, or nearsightedness - clear vision close up but blurry in the distance
  • Hyperopia, or farsightedness - clear vision in the distance but blurry close up
  • Presbyopia - inability to focus close up as a result of aging
  • Astigmatism - focus problems caused by the cornea

The most common symptom is blurred vision. Other symptoms may include double vision, haziness, glare or halos around bright lights, squinting, headaches, or eye strain.

Glasses or contact lenses can usually correct refractive errors. Laser eye surgery may also be a possibility.

NIH: National Eye Institute

Check out the latest treatments for VISION BLURRED

VISION BLURRED treatment research studies

Mirtazapine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Mirtazapine Side Effects

Completed Suicide (237)
Confusional State (206)
Hyponatraemia (180)
Depression (160)
Overdose (148)
Anxiety (147)
Fall (136)
Dizziness (130)
Agitation (130)
Condition Aggravated (123)
Somnolence (117)
Insomnia (113)
Headache (110)
Serotonin Syndrome (109)
Suicidal Ideation (107)
Fatigue (105)
Loss Of Consciousness (104)
Convulsion (103)
Aggression (103)
Suicide Attempt (100)
Nausea (96)
Oedema Peripheral (93)
Dyspnoea (92)
Weight Increased (90)
Tachycardia (90)
Tremor (84)
Malaise (82)
Vomiting (75)
Restless Legs Syndrome (75)
Myalgia (73)
Alanine Aminotransferase Increased (72)
Cardiac Arrest (71)
Inappropriate Antidiuretic Hormone Secretion (71)
Feeling Abnormal (70)
Toxicity To Various Agents (69)
Asthenia (69)
Diarrhoea (67)
Syncope (62)
Hyperhidrosis (61)
Neuroleptic Malignant Syndrome (61)
Pain In Extremity (61)
Electrocardiogram Qt Prolonged (60)
Pyrexia (59)
Aspartate Aminotransferase Increased (58)
Pulmonary Embolism (57)
Arthralgia (56)
Hypotension (56)
Irritability (56)
Pain (55)
Gait Disturbance (54)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

i have been on citalopram and amatripolineand fluxaitne i have been on 15mg of mirtazapine and tryed 30mg the doc has put me on 45mg and i asked if these tablets dont work what is next hes said shrink as i have tryed all the ones he said but i have

My symptoms were tired, weak, unable to sleep. Was prescribed half of a 15 MG Mirtazapine nightly to help me sleep. Has this drug been successful used as a sleeping aid?

The above comment is too stupid, I actually LOLed at you Pete... lol you gave it 2 days and your complaining about the side-effects? and on 15 mgs? LMAO!!! It takes couple weeks at least to cope with the side-effects; just like m

48 year old male, I have suffered depression all my life. Have used SSRI's for the last ten years with good but mixed results. Last year lost my job due to an episode where I ended up throwing my monitor across the office and have not been able to wo

After a nasty experience with citalapram i was advised by my doc to try mirtazapine and it has suitedme very well. only side effect i canreport is an appetite increase. However as i don't carry much weight that isnt a problem.&

Back pain

Been on 90mg mirtazapine for 6 years twice the recomended dose is this considered safe

Body covered in hives

Does mirtazapine have muscles side effects?

Hi, I have been on mittazapine for 10 days, sleepy , tierd all the time and slugish in response to conversation just horrid feel gastly , head ace, The worst went to bed 11pm took the 15mg pill, went to the loo at 3am and collapse

fROM THE DAY i GOT THE INJECTION aCLASTA, i AM FEELING GIDDY AND HAVE LOST MY VISION. w WHAT IS YOUR RESPONSIBILITY ABOUT THIS fROM THE DAY i GOT aCLASTA INJECTION, i AM FEELING

Blurred vision, giddiness,Tiredness,Swelling on feet and hands

M 23 of age.. And via consultant i am taking seroxat(20mg)... about two mouths ago..but still sharp headache occured daily n morning...plus my vision gets blurred n morning..don't nw why..its really annoying... Lik eithr its a medicn side effects o

can advagraf makke you look like you are pregnant? Can this drug affect your eye site--blurry vision

Started taking Bystolic 5mg on Thursday for tachycardia. Sunday, had blurred vision. (Was driving and it was so bad that the interstate signs were blurred!) Stopped medicine and called doctor on Monday. Tuesday, called back because nobody saw f

<b>Describe Your Seroxat Experience Here:</b>Stomach and wierd vision and feeling tired

I was given Celestene by a GP in Frace for bronchial problems/ashma - 4mg for 10 days. It gave me really irritated red skin with spots, overy sensitive skin to my face which tingled when touched, stomach problems and blured vision

<span style='color: #808080;'><b>My son complained of not being able to see to well so I took him to lenscrafters to check his vision since he wore glasses before and had lost them. No big deal I thought, anyway they took some t

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

45 Male on Enbrel 4 + years , My condition is all but gone and I really use no other meds now. Expect a dry cough , Poor night vision ,Memory loss ,and in some cases (345) amniesia. IHAVE noticed a difficulty in learning new&am

VISION BLURRED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Evaluation of Mirtazapine and Folic Acid for Schizophrenia:
Conditions: Schizophrenia;   Negative Symptoms
Interventions: Drug: Mirtazapine and folic acid;   Drug: Mirtazapine, folic acid placebo;   Drug: Mirtazapine placebo, folic acid;   Drug: Mirtazapine placebo, folic acid placebo
Outcome Measures: To compare the efficacy of Mirtazapine and placebo for treatment of symptoms associated with schizophrenia;   To compare the efficacy of folic acid and placebo for treatment of symptoms of schizophrenia;   To compare the efficacy of Mirtazapine and placebo for treatment of negative symptoms of schizophrenia;   To compare the efficacy of folic acid and placebo for treatment of negative symptoms of schizophrenia;   To compare the safety and tolerability of Mirtazapine and placebo in patients with schizophrenia;   To compare the safety and tolerability of folic acid and placebo in patients with schizophrenia
2 Recruiting Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement
Condition: Major Depression
Interventions: Drug: Mirtazapine, paroxetine;   Drug: Mirtazapine;   Drug: paroxetine 20mg QD
Outcome Measures: Change of 17-item Hamilton Depression Scale (HAMD-17) total score;   The proportion of subjects at endpoint with HAMD-17≤7;   The incidence and nature of overall adverse events;   The incidence and nature of drug-related adverse events;   The number of subject withdrawal due to adverse events during double-blind phase
3 Recruiting Pharmacogenetic Study of Mirtazapine Response in Depressed Patients
Condition: Depression
Intervention: Drug: Mirtazapine
Outcome Measures: Mirtazapine response at 2,4,6 weeks and adverse events (A/E) monitoring at 1,2,4,6 weeks;   Biological value at 0 and 6 weeks
4 Unknown  Mirtazapine Versus Placebo in Functional Dyspepsia
Condition: Functional Dyspepsia
Intervention: Drug: Mirtazapine
Outcome Measures: Difference in dyspepsia symptom scores week 8 versus week 0;   Individual symptom severities;   Nepean dyspepsia index for quality of life in functional dyspepsia
5 Recruiting Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Mirtazapine plus gemcitabine;   Drug: Gemcitabine, placebo
Outcome Measures: quality of life;   anxiety and depression scores;   objective response rate;   progress free survival,;   overall Survival;   chemotherapy induced nausea and vomiting
6 Recruiting Mirtazapine for Sleep Disorders in Alzheimer's Disease
Conditions: Alzheimer's Disease;   Sleep Disorders
Intervention: Drug: Mirtazapine
Outcome Measures: Change From Baseline in Nighttime Total Sleep Time;   Change From Baseline in Nighttime Number Of Awakenings;   Change From Baseline in Nighttime Wake After Sleep Onset;   Change From Baseline in in Daytime Total Sleep Time;   Change From Baseline in Number of Daytime Naps;   Change in Cognitive Function (as Measured by the Mini-Mental State Examination);   Change in Activities of Daily Living (The Index of ADL - Katz);   Change of Baseline in Behavioral Variables (BAHAVE-AD Scale);   Change From Baseline in Cognitive Function (Digit Symbol Substitution Test)
7 Recruiting LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression
Condition: Major Depressive Disorder
Intervention: Drug: Mirtazapine
Outcome Measures: increase in weight as measured in the clinic;   Proportion of population achieving clinical response as measured by rate of fall in HAM-D 24 item scores;   Proportion of patients achieving remission at end of study on HAM-D 24 (<11);   Frequency of adverse events;   Percentage adhering to medication
8 Recruiting Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C
Condition: Depression
Interventions: Drug: Mirtazapine;   Other: Supportive psychotherapy
Outcome Measures: Change from baseline in Hamilton Depression Rating Scale (HAMD)-17 at 8 weeks;   Change from baseline in quality of life at 8 weeks;   Genetic polymorphism
9 Recruiting Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)
Condition: Methamphetamine
Interventions: Drug: Mirtazapine;   Drug: Placebo
Outcome Measures: Number of methamphetamine-positive urine tests;   Sexual risk (see description)
10 Recruiting Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Condition: Autism Spectrum Disorders
Interventions: Drug: Placebo;   Drug: Mirtazapine
Outcome Measures: Pediatric Anxiety Rating Scale (PARS);   Clinical Global Impressions (CGI)
11 Unknown  Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
Condition: Depressive Disorder, Major
Interventions: Drug: Mirtazapine;   Drug: Venlafaxine
Outcome Measures: Categorial response to the medication. Categorial response is defined on the basis of CGI Improvement scale and 50% reduction in MADR-S score;   Tolerability of treatment as assessed using the DOTES scale;   Cognitive deficits as judged by the SKT system;   Self assessment of depression and anxiety using Beck's Depression/Anxiety Inventory (BDI/BAI);   Changes is blood levels of homocysteine, folate, vit B12, P11
12 Recruiting Algorithm Guided Treatment Strategies for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Mirtazapine;   Other: modified electroconvulsive therapy;   Other: repetitive transcranial magnetic stimulation;   Drug: Fluoxetine;   Drug: Citalopram;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Trazodone
Outcome Measures: Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7;   Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5;   Frequency and intensity of adverse events;   Quality of life
13 Unknown  Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients
Condition: Depression
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: depressive symptoms;   Distress level
14 Recruiting Strategic Use of New Generation Antidepressants for Depression
Condition: Unipolar Major Depressive Episode
Interventions: Drug: Sertraline;   Drug: Mirtazapine
Outcome Measures: Observer-rated depression severity (PHQ-9);   Self-rated depression severity (BDI-II);   Global rating of side effects (FIBSER)
15 Recruiting Predict Antidepressant Responsiveness Using Pharmacogenomics
Conditions: Depression;   Depressive Symptoms
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measure: Presences of each individual symptom of depression at 1,2,4,6,12 weeks
16 Recruiting Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
Conditions: Depression;   Adverse Reaction to Drug
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: Antidepressant Response at 2,4,6 weeks A/E monitoring at 1,2,4,6 weeks;   Biological value at 0 and 6 weeks
17 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: all pharmacogenetic and biological marker variables cause drug response;   all clinical cause drug response
18 Recruiting Interpersonal Psychotherapy for Treatment Resistant Depression
Condition: Treatment Resistant Depression
Interventions: Other: IPT+ antidepressant drugs;   Drug: fluoxetine;   Drug: sertraline;   Drug: paroxetine;   Drug: Citalopram;   Drug: escitalopram;   Drug: fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Lithium;   Drug: Risperidone;   Drug: tranylcypromine;   Drug: Imipramine;   Drug: amitriptyline;   Drug: Clomipramine;   Drug: nortriptyline;   Drug: trazodone;   Drug: Mirtazapine;   Drug: sulpiride
Outcome Measures: Hamilton Depression Scale (HAM-D) - continuous;   Beck depression Inventory (BDI)
19 Recruiting Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)
Condition: Lumbar Spinal Stenosis
Interventions: Drug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;   Procedure: Lumbar epidural injection;   Other: Joint Mobilizations (spine, sacroiliac, hip);   Other: Individualized exercises: clinical setting;   Other: Group Exercise: community setting
Outcome Measures: Swiss Spinal Stenosis Questionnaire Score;   Self Paced Walking Test
20 Unknown  Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: Depression
Interventions: Device: Thrymatron System IV device (CONSOLIDATION ELECTROCONVUsLIVE THERAPY) plus PHARMACOTHERAPY;   Drug: PHARMACOTHERAPY
Outcome Measures: Hamilton Depression Rating Scale 21 items (HDRS-21);   Mini-Mental State Examination (MMSE 35);   UKU - Adverse effects rating scales;   Demographical Data Memory (MEDABI-20);   Rey Figure;   Trail Making Test A;   Trail Making Test B;   Stroop Test;   Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).;   Vocabulary WAIS (Weschler Adults Intelligence Scale);   Frequency Hospitalization Quotient;   Hospital Day Quotient (HDQ)